Huntington’s Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Symptomatic Treatment, Disease-Modifying Therapies), By End use, By Region, And Segment Forecasts, 2023 - 2030

Report Overview

The global huntington’s disease treatment market size was valued at USD 380.3 million in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 23.20% from 2023 to 2030. The expected label expansion of Ingrezza for treating chorea associated with Huntington’s Disease (HD), high burden of HD in western countries, and strong product pipeline of disease-modifying therapies are anticipated to be major drivers for the market. HD roughly affects 30,000 people in North America, with a prevalence of 5.7 per 100,000 people. HD in children is considerably rarer, accounting for about 5% to 10% of all cases. It affects up to 10 out of 100,000 people in Europe.

HD is a progressive neurological condition caused by CAG expansions in the Huntingtin (Htt) gene. It affects one out of every 10,000 people in the U.S. Healthy people have less than 35 CAG repetitions, whereas HD patients have CAG expansions ranging from 36 to 200. The prevalence varies by more than ten-fold between geographical locations, which can be related to case ascertainment and diagnostic criteria variations. The Asian population has consistently had a lower prevalence, while Europe, North America, and Australia have a higher prevalence. Several small molecules in clinical development are focused on using immunomodulatory drugs to target the overactive immune system in HD.

Key players such as Annexon, Inc. is engaged in the development of ANX005-an experimental monoclonal antibody that targets abnormal C1q activity in complement-mediated neurodegenerative diseases, such as HD. This innovative medication is administered intravenously (IV) and is meant to suppress C1q and the complete classical complement system. In November 2020, the company initiated a phase 2 clinical trial of ANX005 for treating HD patients. Stem cell therapy is also generating interest as a potential treatment for HD. Currently, Cellavita, in collaboration with AzidusPharma, is investigating stem cell therapy, CELLAVITA-HD in phase 2/ 3 ADORE-DH trial.

Huntington’s Disease Treatment Market Impact: 1.01% decrease in revenue growth from 2019 to 2020

However, drug development for HD has faced significant obstacles as several therapies have failed to demonstrate efficacy or were associated with significant toxicity. In March 2021, F. Hoffmann-La Roche Ltd. discontinued the dosing in the phase III GENERATION HD1 study of tominersen in manifest HD. The conclusion was made on the basis of findings of an unblinded Independent Data Monitoring Committee’s (iDMC) preplanned examination of data from the phase III research. During analysis of this data, no new or developing safety signals for tominersen were discovered. COVID-19 pandemic has had a slight negative impact on the market for Huntington’s disease treatment. However, the delays in conducting clinical trials due to the pandemic can delay the entry of pipeline candidates into the market.

Treatment Insights

The symptomatic treatment segment held the largest revenue share of 100.0% in 2022 and is expected to dominate HD treatment market over the forecast period. This growth is due to the availability of symptom management products and patent protection for these products. Xenazine and Austedo are considered first-line therapy for chorea associated with Huntington’s disease. The R&D of potential product candidates for symptom management of Huntington’s disease may contribute to segment growth. In October 2021, the U.S. FDA granted orphan drug designation to SOM BIOTECH’s drug SOM3355 for the treatment of chorea associated with Huntington’s disease. As a result, the product will have exclusivity for 7 years upon U.S. FDA approval.

The disease-modifying therapies segment is anticipated to witness the fastest growth over the forecast period. This is owing to an increase in R&D for disease-modifying therapy coupled with a rise in the demand for advanced products, such as gene therapy and stem cell therapy. The favorable government initiatives such as Fast Track Designation by the U.S. FDA for accelerating the registration process may fuel the market in the coming years. For instance, in September 2021, U.S. FDA granted fast track designation to Sage Therapeutics’s drug, SAGE-718, as a potential treatment for Huntington’s Disease.

End User Insights

The hospital pharmacy segment dominated the market in 2022 with a revenue share of over 57.07%. This dominance can be attributed to their comprehensive healthcare infrastructure, multidisciplinary approach to treatment, expertise in managing complex medications, access to a broad patient population, established relationships with pharmaceutical stakeholders, and commitment to quality care. Hospitals serve as primary healthcare providers for patients with complex conditions like Huntington's disease, and their pharmacies ensure the availability and distribution of specialized medications. With a multidisciplinary team of experts and a focus on patient care, hospital pharmacies have established themselves as key stakeholders in effectively managing and treating Huntington's disease.

The e-commerce segment is expected to expand at a lucrative CAGR over the forecast period. An increase in the usage of the internet and smartphone, ease of ordering medications through an e-commerce platform, and increasing e-commerce services globally are expected to fuel the segment growth in the coming years.

Regional Insights

North America held the largest revenue share of 40.79% in Huntington’s disease treatment market in 2022. This growth is due to the high burden of the disease, increased healthcare expenditure, technological advancements, proactive government initiatives, and increased patient awareness about treatment products for Huntington’s disease. Major players such as H. Lundbeck A/S and Teva Pharmaceutical Industries Ltd. support market growth by introducing symptom management products.

In Asia Pacific, the market for Huntington’s disease treatment is expected to witness significant CAGR over the forecast period due to increased product penetration, untapped potential, and the growing prevalence of the disease in developing countries over the forecast period. A rising number of initiatives being undertaken by governments to improve the health status of the population is expected to drive the growth of the market in the region. However, the market for Huntington’s disease treatment is competitive, which may hamper its growth in this region. For instance, in July 2021, Teva Pharmaceutical Industries Ltd. filed a patent lawsuit against Indian generic manufacturers Lupin Ltd. and Aurobind.

Key Companies & Market Share Insights

Key players are contributing to market growth by adopting various strategies, such as new product development and partnerships to gain a higher market share.

In May 2023, Neurocrine Biosciences’ drug valbenazine in phase 3 trial showed demonstrated a substantial improvement in the management of Huntington's disease-associated chorea. The anticipated approval and subsequent launch of similar drugs throughout the forecast period are expected to drive the growth of the market.

In September 2021, NeuExcell Therapeutics Inc entered a partnership with Spark Therapeutics, Inc. (F. Hoffmann La Roche Ltd. owned subsidiary) for the development of gene therapy for treating HD patients. Under the terms of the agreement, NeuExcell Therapeutics is entitled to receive upfront license fees, R&D, and sales milestone payments of up to approximately USD 190 million and additional product royalties.

In September 2021, Prilenia Therapeutics B.V. announced its participation in H.C. Wainwright 23rd Annual Global Investment Conference, Cantor Virtual Global Healthcare Conference, and European Huntington’s Disease Network for showcasing the topline results of phase 3 candidatepridopidine. These healthcare conferences are an excellent platform for increasing the customer base.

In May 2020, Teva Pharmaceutical Industries Ltd. received NMPA approval for Austedo in China for the treatment of chorea associated with HD. China is the second country after the U.S. to approve AUSTEDO. This geographic expansion of the company is expected to provide a larger patient base and revenue growth. Some of the prominent players in the global Huntington’s disease treatment market include:

• H. Lundbeck A/S

• Teva Pharmaceutical Industries Ltd.

• Bausch Health Companies Inc.

• Hetero

• Lupin

• Hikma Pharmaceuticals PLC

• Dr. Reddy’s Laboratories Ltd.

• Sun Pharmaceutical Industries Ltd.

Huntington’s Disease Treatment Market Report Scope

Global Huntington’s Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global Huntington’s disease treatment market report on the basis of treatment, end-use, and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Symptomatic Treatment

  • Disease-modifying Therapies

• End Use Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • E-commerce

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • Spain

    • France

    • Italy

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Thailand

    • Australia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait